# whatever lit reference i have gotton that could help me in my breast cancer mini project is stored here

https://link.springer.com/article/10.1186/s13045-020-01005-x

- Many studies have shown that gene fusions are closely related to oncogenesis and are appreciated as both ideal cancer biomarkers and therapeutic targets
-Gene fusions in clinical samples are primarily detected by RNA-CaptureSeq.
-Recently, a variety of recurrent gene fusions, including ESR1-CCDC170, SEC16A-NOTCH1, SEC22B-NOTCH2 and ESR1-YAP1, have been identified in breast cancer, indicating that recurrent gene fusion is one of the key drivers for cancer
-Data-mining analysis of RNA sequencing data and other clinical data has identified that the isoforms of peroxiredoxins also can be expected the prognostic biomarkers for predicting overall survival and relapse-free survival in breast cancer

https://www.nature.com/articles/s41392-024-02108-4

<img width="986" height="801" alt="{AA9EA384-9CF9-4A45-BABA-56F12E0CA8E6}" src="https://github.com/user-attachments/assets/b3a236ce-c825-44a9-a236-54a3ccfe7a9c" />

**Genetic predisposition**
Genetic predisposition is the first and the most noticeable part.49 An inherited susceptibility to breast cancer is based on an identified germline mutation in one allele of a moderate to high penetrance susceptibility gene (such as BRCA1/2, CHEK2, PALB2, and TP53). Inactivation of the second allele of tumor suppressor genes would be an early event in this oncogenic pathway.3,50 Protein-truncating variants in five genes (ATM, BRCA1/2, CHEK2, and PALB2) were associated with a risk of breast cancer.6,51 However, above moderate to high penetrance susceptibility gene mutations only account for ~5% of overall breast cancer cases3; attention should be paid to low penetrance susceptibility genetic variation. It mainly includes single-nucleotide polymorphism, insertion/deletion polymorphism, copy number variation, etc. Typical genes, such as CYP17, CYP19, GSTM1, and NQO2, are involved in estrogen synthesis.52,53,54 Although the effect of individual sites of these low penetrance genetic variants is weak, the superposition or synergistic effect of multiple sites plays a crucial role in the risk of breast cancer. Notably, the co-occurrence of genomic alterations like TP53mut-AURKAamp are deeper insights that reveal the underlying genomic changes in breast cancer


# https://pmc.ncbi.nlm.nih.gov/articles/PMC7195715/

DESeq2 remains the gold standard and most popular tool for RNA-seq differential expression (DE) analysis despite newer methods like NBAMSeq (Negative Binomial Additive Model for RNA-Seq, from Ren et al. 2020), primarily due to its proven reliability, ease of use, and benchmark performance.
​

### Key Reasons for DESeq2 Popularity
Robustness for Standard Designs: Excels in small-sample scenarios (e.g., 2-3 replicates per group), common in early RNA-seq, with shrinkage estimation stabilizing variance for low-count genes and strong FDR control. Handles complex multifactor designs seamlessly via GLM framework.
​

**Bioconductor Integration**: Mature R/Bioconductor package with extensive vignettes, community support, and pipelines (e.g., tximport integration), making it beginner-friendly and reproducible.
​

**Benchmark Superiority**: Outperforms or matches edgeR, limma-voom in most simulations/real data for linear effects; widely cited (tens of thousands) vs. niche NBAMSeq.
​

### Why Not Switch to NBAMSeq?
NBAMSeq shines for nonlinear/time-course effects via splines, offering power gains there, but lacks DESeq2's broad validation, simplicity, and ecosystem. It's Bioconductor-available but under-adopted due to added complexity for non-time-series data; users stick with DESeq2 unless nonlinearity is key. Large-sample FDR inflation critiques apply to DESeq2 but don't elevate NBAMSeq as default

| Aspect         | DESeq2                                  | NBAMSeq                              |
| -------------- | --------------------------------------- | ------------------------------------ |
| Best For       | Linear DE, complex designs, small n     | Nonlinear/time-course DE             |
| Power (Linear) | Excellent, benchmark top journals.plos​ | Equivalent pmc.ncbi.nlm.nih​         |
| Ease/Community | High, gold standard pluto​              | Lower, specialized pmc.ncbi.nlm.nih​ |
| FDR Control    | Strong small n; watch large n linkedin​ | Good, info-sharing pmc.ncbi.nlm.nih​ |

## Linear DE and FDR Explained

Linear differential expression (DE) refers to detecting genes whose expression levels differ by a constant amount (additive shift) between conditions, like treatment vs. control, without nonlinear patterns over time or covariates. In RNA-seq tools like DESeq2, this uses a linear generalized linear model (GLM) on log-transformed negative binomial counts, estimating log-fold changes (
log2 control treatment  ) assuming proportional changes independent of baseline expression.
​

FDR stands for False Discovery Rate, a multiple testing correction method controlling the expected proportion of false positives among significant results (e.g., FDR < 0.05 means ~5% of called DE genes are likely false). In DESeq2, raw p-values from Wald or LRT tests are adjusted via Benjamini-Hochberg to yield padj (adjusted p-values), balancing discovery power against genome-wide false positives (~20,000 genes).
​

## Why This Matters in DESeq2 vs. NBAMSeq
DESeq2 excels at linear DE with strong FDR control via empirical Bayes shrinkage on variances, ideal for standard two-group or multifactor designs. NBAMSeq extends to nonlinear trends (e.g., splines for time courses) but assumes users need that complexity; most RNA-seq remains linear, keeping DESeq2 dominant.


# statistical concepts of bulk rna seq

<img width="775" height="676" alt="{122BF73E-97BA-4684-8E8C-9BF80EECB68C}" src="https://github.com/user-attachments/assets/3773efc6-11d9-408b-83d0-9e976fe3bf23" />

# one more resource for bulk rna seq
https://www.cores.emory.edu/eicc/_includes/documents/sections/resources/RNAseq_Methodology.html

read it as it has goof organised info about deseq2

#  Probability Density and Maximum Likelihood Estimation (MLE) are essential tools for effectively analyzing and interpreting continuous data. The Probability Density Function (PDF) offers a clear visualization of how data points are distributed, while maximum likelihood estimation provides a robust method for estimating the parameters that best describe that distribution

https://www.geeksforgeeks.org/machine-learning/probability-density-estimation-maximum-likelihood-estimation/

# wald test used in deseq
https://www.geeksforgeeks.org/machine-learning/wald-test/

# log2FC
<img width="961" height="529" alt="{AB929CA7-3BD1-4798-8853-F55530C70B96}" src="https://github.com/user-attachments/assets/eacbd744-d283-46f9-bc24-7d5790bd5505" />

# By default, DESeq2 implements the Benjamini-Hochberg False Discovery Rate (FDR) multiple testing correction. 
https://www.geeksforgeeks.org/data-science/benjamini-hochberg-procedure/


# what is statistical power and why more statistical power is good in case of benjamin hocheberg statistical analysis in rna - seq

https://chatgpt.com/s/t_6964dcfb93b08191b5c6683463a987b8

this is imp ,read the gpt chat

https://www.geeksforgeeks.org/data-science/benjamini-hochberg-procedure/

Perfect, this all connects nicely. I’ll go **step-by-step**, but still crisp and exam / rebuttal ready.

---

## 1️⃣ Effect size — what it ACTUALLY means (no fluff)

**Effect size** answers this question:

> “How big is the biological change?”

Not *whether* a change exists (that’s p-value), but **how strong** the change is.

In genomics terms 👇
Effect size = **magnitude of differential expression**

---

### In bulk RNA-seq, effect size is usually:

* **Log₂ Fold Change (log₂FC)**

Example:

* log₂FC = 1 → gene expression doubled
* log₂FC = −1 → expression halved
* log₂FC = 0.2 → tiny change (often biologically meh)

📌 Important:

> A gene can be **statistically significant** but have a **small effect size** → not biologically meaningful.

That’s why modern genomics cares about **effect size + significance**, not p-values alone.

---

## 2️⃣ How effect size connects to **statistical power**

These two are tightly linked:

* **Large effect size** → easier to detect → higher power
* **Small effect size** → harder to detect → needs more replicates

Think of it like signal strength 📡
Big signal = easy to spot
Tiny signal = you need more samples to be confident it’s real

---

## 3️⃣ How DESeq2 and edgeR handle this (important!)

### What problem they solve

RNA-seq data:

* are **counts**
* are **overdispersed**
* are **not normally distributed**

So DESeq2 and edgeR model data using a:

> **Negative Binomial distribution**

This allows them to:

* estimate **variance per gene**
* handle biological noise properly
* avoid fake significance

---

### How they improve power

Both tools:

* **borrow information across genes**
* stabilize variance estimates (aka *shrinkage*)
* improve detection of true effects, especially with small sample sizes

DESeq2 specifically:

* shrinks **log₂FC estimates**
* prevents inflated effect sizes for low-count genes

📌 Translation:

> More accurate effect sizes → more reliable statistical power.

---

## 4️⃣ Replicates vs sequencing depth (this is BIG)

This is where Benjamin-Horshberg-type arguments usually come in.

### Two ways to spend your budget 💸

#### Option A:

* Few samples
* Very deep sequencing

#### Option B:

* More biological replicates
* Moderate sequencing depth

👉 **Option B almost always gives higher statistical power**

---

### Why?

Sequencing depth:

* reduces **technical noise**
* helps detect low-expressed genes (to a limit)

Biological replicates:

* reduce **biological variance**
* improve variance estimation
* directly increase power in DESeq2/edgeR

📌 Key principle:

> **You can’t average away biological variability with more reads.**

That’s why:

* 3 vs 6 replicates matters more than
* 30M vs 100M reads per sample (after a point)

---

## 5️⃣ Why effect size + power matter in genomics (real consequences)

In RNA-seq we test:

* 15,000–25,000 genes
* under strict multiple-testing correction (FDR)

If power is low:

* true DE genes fail FDR
* pathways disappear
* biology looks “quiet” even when it isn’t

If effect size is ignored:

* tiny, useless changes get hyped
* conclusions don’t replicate

Modern best practice:

> **Report log₂FC + FDR + confidence/shrinkage**

---

## 6️⃣ One clean summary (viva / rebuttal ready)

> In bulk RNA-seq, effect size refers to the magnitude of differential gene expression, typically measured as log₂ fold change. Statistical power reflects the ability to detect these true expression changes. Tools like DESeq2 and edgeR increase power by modeling count data with negative binomial distributions and stabilizing variance estimates. Increasing biological replicates improves power more effectively than increasing sequencing depth, making replicate-rich designs essential for reliable and biologically meaningful genomic inference.

---

If you want next, we can:

* turn this into a **reviewer-proof rebuttal paragraph**
* add **formulas intuitively**
* or compare **bulk vs single-cell power mathematically** 👀


-----------------------

# shrinkage and vaiance a trade offs (goood topic must read again)

Alright, let’s do this **properly, conceptually, and Nature-journal aligned**.
No fluff, no blogs, no YouTube logic — only what would survive **Nature Methods / Nature Biotechnology–level reasoning**.

I’ll structure this exactly like a **methods + discussion explanation**.

---

# Shrinkage and Variance in Bulk RNA-seq

*(Purpose, use cases, limitations — Nature-journal framing)*

---

## 1️⃣ Variance in bulk RNA-seq: what it is and why it exists

### What “variance” means (precisely)

In bulk RNA-seq, **variance** measures how much a gene’s read counts **fluctuate across biological replicates** under the same condition.

Formally (Nature-style thinking):

> Variance reflects the combined effect of **biological variability** and **technical noise** on observed gene expression counts.

---

### Why RNA-seq variance is special (not like microarrays)

Nature Methods emphasizes that RNA-seq data:

* are **discrete counts**
* show **mean–variance dependence**
* exhibit **overdispersion** relative to Poisson expectations

That is why RNA-seq requires a **Negative Binomial (NB)** model.

> **Key Nature insight:**
> Variance increases with mean expression and differs gene-to-gene.

This breaks assumptions of classical normal models.

---

### Sources of variance (important distinction)

#### 1️⃣ Biological variance (dominant in human cancer data)

* patient heterogeneity
* tumor purity differences
* immune infiltration
* clonal diversity

#### 2️⃣ Technical variance

* library prep
* sequencing depth
* GC bias
* batch effects

📌 **Nature consistently stresses**:

> Biological variance cannot be averaged away by deeper sequencing.

---

## 2️⃣ Why variance estimation is hard (core statistical problem)

### The real problem Nature papers highlight

For each gene, you want to estimate:

* mean expression
* dispersion (variance parameter)

But:

* most experiments have **small sample sizes**
* per-gene variance estimates become **extremely noisy**

Result without correction:

* low-count genes show wildly unstable variance
* false positives inflate
* effect sizes exaggerate

This is the *exact problem DESeq2 and edgeR were designed to fix*.

---

## 3️⃣ Shrinkage: what it ACTUALLY means (Nature definition)

### Conceptual definition

> **Shrinkage is a regularization strategy that pulls noisy, gene-specific estimates toward a global trend learned from the data.**

It is not:

* deleting information
* forcing values to zero
* hiding biology

It is:

* **reducing estimation error**

Nature papers frame this as **empirical Bayes regularization**.

---

## 4️⃣ Shrinkage of variance (dispersion shrinkage)

### Why variance is shrunk

Per-gene dispersion estimates:

* are unreliable with few replicates
* especially unstable for lowly expressed genes

So Nature-approved methods:

* estimate a **global mean–dispersion trend**
* shrink individual gene dispersions toward this trend

Mathematically:

> Observed dispersion = gene signal + estimation noise
> Shrinkage reduces the noise component.

---

### Purpose of variance shrinkage

Nature Methods highlights three purposes:

1️⃣ **Stabilize statistical tests**
2️⃣ **Control false discovery rate (FDR)**
3️⃣ **Prevent low-count genes from dominating results**

Without it:

* p-values become anti-conservative
* DE lists explode with artifacts

---

### Use cases (variance shrinkage)

✔ Small–moderate sample sizes
✔ Human tissue / cancer datasets
✔ High biological heterogeneity
✔ Exploratory + confirmatory analyses

This is why DESeq2 is favored in **clinical genomics**.

---

### Limitation of variance shrinkage

Nature is very clear on this:

⚠️ If a gene truly has **exceptionally high biological variability**, shrinkage may **underestimate** its dispersion.

Consequence:

* reduced sensitivity for highly variable genes
* conservative bias

📌 Nature’s stance:

> This trade-off is preferable to inflated false positives.

---

## 5️⃣ Shrinkage of effect size (log₂FC shrinkage)

### Why effect size needs shrinkage

Raw log₂ fold changes:

* explode for low-count genes
* are poorly estimated with few samples
* exaggerate biological importance

Nature papers explicitly warn:

> Large fold changes in low-abundance genes are often statistical artifacts.

---

### What effect size shrinkage does

Effect size shrinkage:

* pulls exaggerated log₂FC values toward zero
* scales shrinkage by **uncertainty**
* preserves large effects when evidence is strong

This improves:

* gene ranking
* volcano plot interpretability
* downstream biological conclusions

---

### Purpose of log₂FC shrinkage (Nature framing)

1️⃣ **Prevent overinterpretation of weak signals**
2️⃣ **Improve reproducibility across datasets**
3️⃣ **Enable biologically meaningful thresholds**

This is critical for:

* biomarker discovery
* translational genomics
* clinical interpretation

---

## 6️⃣ Shrinkage + variance together: why Nature supports this framework

Nature journals emphasize that RNA-seq analysis must balance:

| Goal        | Risk                |
| ----------- | ------------------- |
| Sensitivity | False positives     |
| Precision   | Missed weak signals |
| Stability   | Over-regularization |

Shrinkage provides:

* **bias–variance trade-off**
* controlled inference
* reproducible results

> Nature’s implicit position:
> Conservative but stable inference is superior to noisy sensitivity.

---

## 7️⃣ Limitations of shrinkage (critical, honest view)

Nature does **not** present shrinkage as perfect.

### Key limitations

❌ Reduced sensitivity for:

* rare transcripts
* highly variable genes

❌ True extreme effects may be slightly underestimated

❌ Requires correct experimental design:

* batch effects must be modeled
* shrinkage cannot fix confounding

Shrinkage is a **statistical safeguard**, not a design substitute.

---

## 8️⃣ One Nature-style summary paragraph (save this)

> In bulk RNA-seq, variance arises from both biological heterogeneity and technical noise, necessitating statistical models that accommodate overdispersed count data. Shrinkage approaches, as implemented in modern differential expression frameworks, stabilize dispersion and effect size estimates by borrowing information across genes. This regularization reduces estimation noise, improves control of false discoveries, and enhances interpretability, particularly in small or heterogeneous datasets. While shrinkage may reduce sensitivity for highly variable genes, Nature-level consensus favors this trade-off as essential for reproducible and biologically meaningful inference.

-----------------

# “Mean–variance dependence”

# Bulk RNA-seq data exhibit strong mean–variance dependence and overdispersion relative to Poisson expectations, reflecting both technical noise and biological heterogeneity. Negative binomial models address this structure by explicitly modeling dispersion; however, reliable inference still depends on appropriate experimental design. Shrinkage stabilizes variance and effect size estimates by reducing estimation noise, but it cannot correct for confounding or systematic biases such as batch effects. Consequently, batch effects must be explicitly modeled, as shrinkage serves as a statistical safeguard rather than a substitute for proper experimental design.

# read this too again very good

Perfect — this is the **exact right place to slow down and really understand the logic**.
I’ll explain those two bullets **first**, then connect them cleanly to the three statements you quoted.

No fluff, Nature-Methods style reasoning.

---

## 1️⃣ “Mean–variance dependence” — what this really means

### The naïve assumption (which fails)

In simple models, we often assume:

> variance is constant, regardless of the mean

That’s roughly true for **normally distributed data**.

But RNA-seq data are **counts**, not continuous values.

---

### What Nature means by *mean–variance dependence*

In bulk RNA-seq:

> **Genes with higher average expression automatically show higher variance across samples.**

Formally:

* lowly expressed genes → low mean, high relative noise
* highly expressed genes → high mean, higher absolute variance

So:

```
variance ≠ constant
variance = f(mean)
```

This is **mean–variance dependence**.

---

### Why this matters

If you ignore this:

* low-count genes look artificially variable
* statistical tests become biased
* false positives increase

That’s why RNA-seq **cannot** be analyzed with simple linear models without correction.

---

## 2️⃣ “Overdispersion relative to Poisson expectations”

### What Poisson assumes

A Poisson model assumes:

```
variance = mean
```

This would mean:

* all variability comes from random sampling
* no extra biological noise

---

### What Nature observed in real RNA-seq data

In real bulk RNA-seq (especially human tissues):

```
observed variance > mean
```

This extra variability is called **overdispersion**.

Sources:

* biological heterogeneity
* tumor purity differences
* immune infiltration
* batch effects
* inter-individual variability

📌 **Key Nature insight**
RNA-seq variability is not just counting noise — it’s biological.

---

### Why this breaks Poisson

If you use Poisson:

* variance is underestimated
* p-values become too small
* you get many false positives

Hence, Nature journals strongly reject Poisson models for bulk RNA-seq.

---

## 3️⃣ Why Negative Binomial is used (linking both points)

The **Negative Binomial (NB)** model allows:

```
variance = mean + dispersion × mean²
```

This does two things:

1. Handles mean–variance dependence
2. Explicitly models overdispersion

This is the statistical foundation of **DESeq2 and edgeR**.

---

## 4️⃣ Now connect this to your three key statements

### 🔹 “Batch effects must be modeled”

Batch effects add **systematic variance**.

NB + shrinkage:

* assume remaining variance is random
* cannot distinguish batch-driven shifts from biology

So if batch is unmodeled:

* dispersion is inflated
* shrinkage pulls effects toward zero
* true biological signals are lost

📌 **Nature logic**

> Shrinkage regularizes noise, not bias.

---

### 🔹 “Shrinkage cannot fix confounding”

Confounding means:

* batch is correlated with condition
* e.g., all TNBC samples sequenced in batch A

Shrinkage:

* reduces variance
* stabilizes estimates

But it **cannot disentangle cause**.

So:

* biased design → biased results
* shrinkage only makes them *consistently wrong*

---

### 🔹 “Shrinkage is a statistical safeguard, not a design substitute”

This sentence is the **philosophical takeaway**.

What shrinkage CAN do:

* control false positives
* stabilize noisy estimates
* improve reproducibility

What shrinkage CANNOT do:

* fix bad experimental design
* remove confounding
* replace biological replication

Nature journals repeatedly emphasize:

> Good design first, regularization second.

---

## 5️⃣ One clean Nature-style synthesis paragraph

You can reuse this verbatim:

> Bulk RNA-seq data exhibit strong mean–variance dependence and overdispersion relative to Poisson expectations, reflecting both technical noise and biological heterogeneity. Negative binomial models address this structure by explicitly modeling dispersion; however, reliable inference still depends on appropriate experimental design. Shrinkage stabilizes variance and effect size estimates by reducing estimation noise, but it cannot correct for confounding or systematic biases such as batch effects. Consequently, batch effects must be explicitly modeled, as shrinkage serves as a statistical safeguard rather than a substitute for proper experimental design.

------------------

# prompt-- find anything related to breast cancer from nature hournal only highly credible source that`ll help me in my bulk rna seq analysis of subtypes as a beginneralso categorie thing sinto secti9ons such as preprocessing related stuff,fastq related stuff,sttatistical concepts related stuff,limitations,design of experiment,why one concept over other,result reading,map reading,common pitfalls, these all should be from nature journal only


## 


